Can Fite Biopharma Stock Analysis

Can Stock Analysis Notes

The book value of the company was currently reported as 0.0. The company recorded a loss per share of 2.6. Can Fite Biopharma last dividend was issued on the 10th of May 2019. The entity had 1:10 split on the 9th of January 2023. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people. For more info on Can Fite Biopharma please contact Pnina Fishman at 972 3 924 1114 or go to https://www.canfite.com.

Can Fite Biopharma Investment Alerts

Can Fite Biopharma Upcoming and Recent Events

Can Largest EPS Surprises

View All Earnings Estimates

Can Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.95 M.

Can Profitablity

Management Efficiency

Can Fite Biopharma has return on total asset (ROA) of (0.5746) % which means that it has lost $0.5746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5762) %, meaning that it created substantial loss on money invested by shareholders. Can Fite's management efficiency ratios could be used to measure how well Can Fite manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.8. The current Return On Capital Employed is estimated to decrease to -1.08. At this time, Can Fite's Other Current Assets are most likely to increase significantly in the upcoming years. The Can Fite's current Total Current Assets is estimated to increase to about 10.3 M, while Non Currrent Assets Other are forecasted to increase to (107.7 K).

Technical Drivers

As of the 24th of November, Can Fite shows the Mean Deviation of 2.76, standard deviation of 4.0, and Risk Adjusted Performance of (0.01). Can Fite Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Can Fite Biopharma variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Can Fite Biopharma is priced correctly, providing market reflects its regular price of 1.96 per share. Please also double-check Can Fite Biopharma jensen alpha, which is currently at (0.21) to validate the company can sustain itself at a future point.

Can Fite Biopharma Price Movement Analysis

Can Fite Outstanding Bonds

Can Fite Predictive Daily Indicators

Can Fite Forecast Models

Can Fite's time-series forecasting models are one of many Can Fite's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Can Fite's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Can Fite prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Can shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Can Fite. By using and applying Can Stock analysis, traders can create a robust methodology for identifying Can entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Can analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Can analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Can Fite Biopharma stock analysis indicators help investors evaluate how Can Fite stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Can Fite shares will generate the highest return on investment. By understating and applying Can Fite stock analysis, traders can identify Can Fite position entry and exit signals to maximize returns.

When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.